Track topics on Twitter Track topics that are important to you
South Korean firm Celltrion Healthcare is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar, Remsima (infliximab), which was rolled out across Europe ...
South Korea's Celltrion and Samsung Bioepis are competing hard to grab a slice of the burgeoning global biosimilar market. Celltrion’s Remicade biosimilar has already been widely launched and may on...
Biogen moves to halt Celltrion from selling a rituximab biosimilar in South Korea by seeking a patent scope confirmation trial as the South Korean firm gears up to launch its second biosimilar. But Ce...
Medidata's ClinicalCloud will provide scalable technology to Celltrion's biosimilars development programs. Date: Thu, 2016-01-21 (All day) ...
Celltrion’s supply chain and warehousing procedures ensure the safe storage of Remicade biosimilars as demand fluctuates across markets, the drugmaker says.
With the favorable backing of a US FDA advisory panel on Feb. 9, which followed a positive review by regulators, Celltrion and its partner, Pfizer unit Hospira, are well on their way to putting the fi...
Biosimilar acceptance among physicians has doubled to 80% since 2013, according to a survey presented at by copycat biologic distributor Celltrion Healthcare.
Celltrion Inc. (KOSDAQ:068270) presented data from 10 real-world switching studies showing that biosimilar infliximab (CT-P13) had "comparable efficacy and safety" to reference product Remicade inflix...